AIDSmeds founder Peter Staley interviewed Dr. Donald Kotler, chief of gastroenterology at St. Luke's-Roosevelt Hospital in New York, and a longtime researcher of wasting, lipodystrophy, and metabolic problems in people with HIV. Kotler discusses TH-9507, an experimental drug for reducing fat around the gut; Fosamax helping with bone loss in HIVers; high-fat diets in people with HIV; and whether lipid-lowering drugs work well for HIVers.

Study Finds Viread Advantages in Black Patients

Twice-Daily Kaletra Possibly Better for Some Patients

Once-Daily Viramune Strikes Out

Fewer Side Effects with Videx/Epivir vs. Combivir

Still No Clear Benefit of Treating Early HIV (Reuters Health)

One in 10 Infected with Drug-Resistant HIV

Non-Nuke TMC-278 Comparable to Sustiva

Integrase Inhibitor Elvitegravir (GS-9137) Shows Well

Isentress (MK-0518) Results Prove Promising

Encouraging Data from Two Maraviroc Studies

Baraclude Induces HIV Drug Resistance

HIV+ Less Responsive to Lipid-Lowering Meds

Study Says Less Fat for Lower Lipids

Shift in Cancer-Related Deaths in HIV

TH9507 Shows Promise for Lipodystrophy

More Lipoatrophy with Sustiva vs. Kaletra

Zetia Lowers 'Bad' LDL Cholesterol

Fosamax, Calcium, and Vitamin D for Bone Weakness

Breastfeeding Safer for Some HIV+ Mothers (Reuters Health)

The Plot Thickens: HIV Treatment Challenges

The Skinny on Metabolic Complications

What's New? Update on Experimental Agents

Diary of a Doc: On the Origins of HIV

Diary of a Doc: New Strategies for HIV-Herpes Coinfection